Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2006; 27(04): 7-12
DOI: 10.1055/s-0041-1733184
Original Article

A Pilot Study of BEACOPP Chemotherapy with or without Involved field Radiotherapy in Hodgkin’s Lymphoma

Naresh Somani
Department of Medical Oncology, Bhagwan Mahaveer Cancer Hospital & Research Center, JLN Marg, Jaipur-302017, India
,
P Agarwal
Department of Medical Oncology, Bhagwan Mahaveer Cancer Hospital & Research Center, JLN Marg, Jaipur-302017, India
,
N Patni
Department of Radiotherapy, Bhagwan Mahaveer Cancer Hospital & Research Center, JLN Marg, Jaipur-302017, India
,
A Parikh
Department of Pathology, Bhagwan Mahaveer Cancer Hospital & Research Center, JLN Marg, Jaipur-302017, India
,
D Gupta
Department of Radiology, Bhagwan Mahaveer Cancer Hospital & Research Center, JLN Marg, Jaipur-302017, India
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
23 March 2022

© 2006. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Deihl V ,Frankalin J, Hasenclever D et al. BEACOPP ,a new dose escalated and accelerated regimen, is at least as effective as COPP/ABVD in patients with advanced-stage Hodgkin’s lymphoma: interim report from a trial of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 1998;16:3810-21.
  • 2 Horning S, Rosenberg S, Hoppe R. Brief chemotherapy (Stanford V) and adjuvant radio therapy for bulky or advanced Hodgkin’s disease: an update. Ann Oncol 1996;7[Suppl 4]:105.
  • 3 De Vita VT Jr., Simon RM, Hubbard et al. curability of advanced Hodgkin’s disease with chemotherapy. Long term follow-up of MOPP treated patients at the National Cancer Institute Ann Intern Med 1980:92:587- 95.
  • 4 Diehl V et al. Standard & increased dose BEACOPP chemotherapy with COPP-ABVD for advanced Hodgkin’s disease New Eng J Med 2003;348;2386-95.
  • 5 Bonadanna G. Zueali R. Monfardini et al. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin ,vinblastine and imidazol carboximide versus MOPP. Cancer 1975:36:252-60.
  • 6 Lukes RJ, Craver L,Hall TC, et al:Report of the nomiclature committee.Cancer Res 1966;26 :1311,
  • 7 Bennett MH, MacLennan Ka,Easterling MJ,et al: The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin’s disease: Analysis of 271 nonlaparotomized cases. Clin Radiol 1983;34:497-501.
  • 8 Carbone PP, Kaplan HS, Musshoff K,et al : M. Report of the committee of Hodgkin’s disease staging classification.Cancer Res 1971;31:1860-61.
  • 9 Josting A. Franklin J. May M, et al, New prognostic score based on treatment outcome of patients with relapsed Hodgkin’s lymphoma registered in the database of the German Hodgkin’s Lymphoma study Group. J.Clin Oncol 2002;20:221-30.
  • 10 Conners JM. Klimo P.Adams G.et al. Treatment of advanced Hodgkin’s disease with chemotherapy comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP & ABVD :A report from the national cancer institute of canada clinical trials group.J Clin Oncol 1997:15:1638-45.[Erratum,J Clin oncol 1997;15:2762]
  • 11 Bonfante V. Santoro A. Viviani S. et al. Outcome of patients with Hodgkin’s disease failing after primary MOPP. ABVD J Clin Oncol 1997;15:528-34.
  • 12 Loeffler M, Brosteanu O, hasenclever D et al : Meta _analysis of chemotherapy versus combined modality treatment trials in Hodgkin’s disease: international database on Hodgkin’s disease Overview study Group.J Clin Oncol 1998;16:818-829.
  • 13 Duggan D. petrom G. Johnson j. et al. MOPP/ABV versus ABVD for advanced Hodgkin’s disease A preliminary report of CALGB 8952 (with SWOG, ECOG, NCIC) prog proc Am Soc Clin Oncol 1997;16:12a. Abstract.